NeOnc Technologies schedules FDA end-of-Phase 1 meeting for brain cancer drug NEO212

Bitget2026/09/28 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NeOnc Technologies scheduled an in-person FDA End-of-Phase 1 meeting for NEO212 on Nov. 17, 2026.
Phase 1 results were already reported; the company flagged durable disease control in two heavily pretreated brain cancer patients.
Management framed the outcome as supportive of advancing NEO212 into Phase 2 and pursuing a registrational strategy.
FDA feedback will guide a revised Phase 2 plan, including patient population and endpoints, with no assurance of accelerated approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834748) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NeOnc Technologies schedules FDA end-of-Phase 1 meeting for brain cancer drug NEO212

You may also like

Crypto prices